A case report on primigravida with myasthenia gravis: outcome of pregnancy
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20232375Keywords:
Elective caesarean section, Myasthenia gravis, NICU, PrimigravidaAbstract
Primigravida refers to a woman who is pregnant for the first time. It is a unique experience for the woman. Usually, any minor alignment during this time will lead to anxiety. The prevalence rate of myasthenia gravis in pregnancy is 1 in 20,000. The main reason behind the cause of the disease is improper secretion of acetylcholine, huge secretion of cholinesterase, and non-responsive muscle fibers. The purpose of this case study is to introduce the outcome of pregnancy with myasthenia gravis. This case was taken at X private hospital. A 27-year-old primigravida woman with 38 weeks of pregnancy was the first known case of myasthenia gravis. She was diagnosed with myasthenia gravis thymic hyperplasia in November 2020. The patient is then managed with a surgical procedure, i.e., thymectomy, on 18 September 2021. The patient was receiving distinon (pyridostigmine) 60 mg. It requires the intraoperative collaboration of the neurology and obstetrics departments in managing myasthenia gravis during pregnancy. A successful elective caesarean section was done on the patient's request under spinal anaesthesia on 13 April 2023. The male newborn, with a birth weight of 2.825 gm was delivered. The newborn was transferred to the NICU for further surveillance and did not show any sign of muscular weakness. The baby was healthy at the time of discharge.
References
National Organization for Rare Disorders. Myasthenia Gravis, 2022. Available at: https://rarediseases.org/rare-diseases/myasthenia-gravis/. Accessed 17 May 2023.
Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.
Grob D, Brunner N Namba T, Pagala H. Lifetime course of myasthenia gravis. Musc Nerv. 2008;37(2):141-9.
Gilhus NE, Verschuuren. Pregnancy and myasthenia gravis. J Neurol. 2011;258(9):447-52.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins; 2012: 46-47.
Chaudhry SA, Vignarajah B, Koren G. Myasthenia gravis during pregnancy. Canad Fami Physi. 2012;58(12):1346-9.
Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Ind J Pharmacol. 2018;50(6):302.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Mark A, et al. Randomized trial of thymectomy in Myasthenia Gravis. N Eng J Medi. 2016;375(6):511-22.
Cimpoca-Raptis BA, Ciobanu AM, Gica N, Peltecu G, Mitrea D, Panaitescu AM. Fetal surveillance in pregnancies with myasthenia gravis. Medicina. 2021;57(11):1277.
Hamel J, Ciafaloni E. An update: Myasthenia Gravis and Pregnancy. Neurol Clin. 2018;36(2):355-65.
Myasthenia Gravis Foundation of America (MGFA), 2023. Available at: https://myasthenia.org/ Professionals/Clinical-Overview-of-MG. Accessed on 01 June 2015.
Chabert L, Benhamou D. Myasthenia gravis, pregnancy and delivery: a series of ten cases. Elsevier J. 2004;23(5):459-64.
Duff GB. Preclampsia and the patient with myasthenia gravis. Obstet Gynaecol. 1979;54(3):355-8.
Cohen A, London RS, Goldstein PJ. Myasthenia gravis and pre eclampsia. Obstet Gynecol. 1976;48(1):35-7.
Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratol. 199;51(1):45-6.
Martinez-Rueda JO, Arce-Salinas CA, Kraus A, Alcocer-Varela J, Alarcon-Segovia D. Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus. 1996;5(2):113-9.
Czeizel AE, Rockenbauer M. Population‐based case‐control study of teratogenic potential of corticosteroids. Teratol. 1997;56(5):335-40.
Rodríguez‐Pinilla E, Luisa Martínez‐Frías M. Corticosteroids during pregnancy and oral clefts: a case‐control study. Teratol. 1998;58(1):2-5.
Gaudier FL, Santiago-Delpin E, Rivera J, Gonzales Z. Pregnancy after renal transplantation. Surg Gynecol Obstet.1988;167(6):533–43.
